稳定CYP1B1表达的B7-H3介导的二维基化促进了结直肠癌的化疗耐药性
Huan Liu1, Guifang Li1, Chenjie Shen1
1Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi 214062, Jiangsu Province, China.
概括
在结直肠癌 (CRC) 中,高B7-H3表达通过稳定CYP1B1.1.促进化疗耐药性. 针对B7-H3-CYP1B1相互作用可以克服CRC患者的治疗耐药性.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 免疫治疗是一种免疫疗法.
背景情况:
- 结肠直肠癌 (CRC) 是全球癌症死亡的主要原因.
- 化疗耐药性显著恶化了CRC患者的预后.
- B7-H3是一种新兴的瘤标志物和免疫治疗点,与CRC预后不佳有关.
研究的目的:
- 研究B7-H3在促进结直肠癌中耐化疗的作用.
- 阐明B7-H3介导化学抵抗的潜在分子机制.
- 确定B7-H3-CYP1B1相互作用作为CRC的潜在治疗标.
主要方法:
- 在结直肠癌组织中分析B7-H3表达.
- 在体内和体外实验中评估B7-H3对化学抵抗的影响.
- 研究B7-H3-CYP1B1信号通路,包括无处不在和蛋白质稳定.
主要成果:
- 在结直肠癌组织中观察到B7-H3表达的增加.
- 在CRC模型中,B7-H3表达的增加增强了对化疗的耐药性.
- 发现B7-H3通过抑制其无化,从而促进化学抗药性来稳定CYP1B1.
结论:
- B7-H3-CYP1B1轴在结直肠癌中介化疗耐药性方面发挥着至关重要的作用.
- 针对B7-H3-CYP1B1相互作用是一个有前途的战略,以克服CRC中的化学抵抗.
- B7-H3代表了改善结直肠癌治疗结果的重要治疗标.
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Covalently Linked Protein Regulators
6.7K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.7K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K


